Segment, Geographic and Other Revenue Information (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended				6 Months Ended
	Jul. 01, 2012		Jul. 03, 2011		Jul. 01, 2012		Jul. 03, 2011
Segment Reporting Information [Line Items]
Revenues	$ 15,057		$ 16,485		$ 29,942		$ 32,509
R&D Expenses	1,699	[1]	2,231	[1]	3,753	[1]	4,311	[1]
Earnings	4,484	[2]	3,598	[2]	6,919	[2]	6,608	[2]
Primary Care [Member]
Segment Reporting Information [Line Items]
Revenues	4,018	[3]	5,870	[3]	8,115	[3]	11,311	[3]
R&D Expenses	251	[3]	304	[3]	492	[3]	627	[3]
Earnings	2,617	[2],[3]	3,806	[2],[3]	5,287	[2],[3]	7,357	[2],[3]
Specialty Care And Oncology [Member]
Segment Reporting Information [Line Items]
Revenues	3,820		4,038		7,688		8,276
R&D Expenses	326		376		699		722
Earnings	2,657	[2]	2,581	[2]	5,253	[2]	5,459	[2]
Established Products and Emerging Markets [Member]
Segment Reporting Information [Line Items]
Revenues	5,301	[4]	4,732	[4]	10,401	[4]	9,277	[4]
R&D Expenses	66	[4]	79	[4]	139	[4]	135	[4]
Earnings	3,076	[2],[4]	2,484	[2],[4]	6,253	[2],[4]	4,965	[2],[4]
Animal Health and Consumer Healthcare [Member]
Segment Reporting Information [Line Items]
Revenues	1,853		1,769		3,607		3,489
R&D Expenses	102		106		194		207
Earnings	608	[2]	514	[2]	1,103	[2]	1,003	[2]
Reportable Segments [Member]
Segment Reporting Information [Line Items]
Revenues	14,992		16,409		29,811		32,353
R&D Expenses	745		865		1,524		1,691
Earnings	8,958	[2]	9,385	[2]	17,896	[2]	18,784	[2]
Other business activities [Member]
Segment Reporting Information [Line Items]
Revenues	65	[5]	76	[5]	131	[5]	156	[5]
R&D Expenses	671	[5]	858	[5]	1,346	[5]	1,704	[5]
Earnings	(674)	[2],[5]	(860)	[2],[5]	(1,355)	[2],[5]	(1,702)	[2],[5]
Corporate [Member]
Segment Reporting Information [Line Items]
R&D Expenses	229	[6]	312	[6]	515	[6]	637	[6]
Earnings	(1,610)	[2],[6]	(1,836)	[2],[6]	(3,423)	[2],[6]	(3,680)	[2],[6]
Purchase Accounting Adjustments [Member]
Segment Reporting Information [Line Items]
R&D Expenses	(2)	[7]	3	[7]	(2)	[7]	3	[7]
Earnings	(1,164)	[2],[7]	(1,727)	[2],[7]	(2,610)	[2],[7]	(3,500)	[2],[7]
Acquisition-related Costs [Member]
Segment Reporting Information [Line Items]
R&D Expenses					5	[8]	3	[8]
Earnings	(237)	[2],[8]	(592)	[2],[8]	(420)	[2],[8]	(1,162)	[2],[8]
Certain significant items [Member]
Segment Reporting Information [Line Items]
R&D Expenses	37	[9]	177	[9]	344	[9]	250	[9]
Earnings	(696)	[2],[9]	(657)	[2],[9]	(2,763)	[2],[9]	(1,866)	[2],[9]
Other unallocated [Member]
Segment Reporting Information [Line Items]
R&D Expenses	19	[10]	16	[10]	21	[10]	23	[10]
Earnings	$ (93)	[10],[2]	$ (115)	[10],[2]	$ (406)	[10],[2]	$ (266)	[10],[2]

[1] Exclusive of amortization of intangible assets, except as disclosed in Note 9B. Goodwill and Other Intangible Assets: Other Intangible Assets.

[2] Income from continuing operations before provision for taxes on income.

[3] Revenues and Earnings from the Primary Care segment decreased in the three and six months ended July 1, 2012 as compared to the prior year mainly due to the loss of exclusivity for Lipitor in the U.S. and the subsequent shift in the reporting of Lipitor U.S. results to the Established Products business unit.

[4] Revenues from the Established Products and Emerging Markets segment increased in the three months and six months ended July 1, 2012 as compared to the prior year primarily due to additional products losing exclusivity and moving to the Established Products unit, as well as increased sales in emerging markets. Earnings from the Established Products and Emerging Markets segment increased in the three months and six months ended July 1, 2012 as compared to the prior year, primarily due to additional products losing exclusivity and moving to the Established Products unit, increased sales in emerging markets, as well as a change in the mix of products.

[5] Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, and the research and development costs managed by our Worldwide Research and Development organization and our Pfizer Medical organization.

[6] Corporate for R&D expenses includes, among other things, administration expenses and compensation expenses associated with our research and development activities and for Earnings includes, among other things, administration expenses, interest income/(expense), certain compensation and other costs not charged to our operating segments.

[7] Purchase accounting adjustments include certain charges related to the fair value adjustments to inventory, intangible assets and property, plant and equipment.

[8] Acquisition-related costs can include costs associated with acquiring, integrating and restructuring newly acquired businesses, such as transaction costs, integration costs, restructuring charges and additional depreciation associated with asset restructuring (see Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives for additional information).

[9] Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include restructuring charges and implementation costs associated with our cost-reduction and productivity initiatives that are not associated with an acquisition, the impact of certain tax and/or legal settlements and certain asset impairments. For Earnings in the second quarter of 2012, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $71 million, (ii) charges for certain legal matters of $483 million, (iii) certain asset impairment charges of $77 million and (iv) other charges of $65 million (see Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives and Note 4. Other Deductions--Net for additional information). For Earnings in the second quarter of 2011, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $256 million, (ii) charges for certain legal matters of $53 million, (iii) certain asset impairment charges of $332 million and (iv) other charges of $16 million (see Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives and Note 4. Other Deductions--Net for additional information). For Earnings in the first six months of 2012, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $888 million, (ii) charges for certain legal matters of $1.3 billion, (iii) certain asset impairment charges of $489 million and (iv) other charges of $128 million (see Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives and Note 4. Other Deductions--Net for additional information). For Earnings in the first six months of 2011, certain significant items include: (i) restructuring charges and implementation costs associated with our cost-reduction and productivity initiatives that are not associated with an acquisition of $828 million, (ii) charges for certain legal matters of $525 million, (iii) certain asset impairment charges of $489 million and (iv) other charges of $24 million (Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives and Note 4. Other Deductions--Net for additional information). For R&D in all periods presented, certain significant items primarily reflect additional depreciation--asset restructuring and implementation costs.

[10] Includes overhead expenses associated with our manufacturing and commercial operations not directly attributable to an operating segment.